Noncommunicable diseases (NCDs) are the leading causes of death globally, killing more people each year than all other causes combined. Contrary to popular opinion, available data demonstrate that nearly 80% of NCD deaths occur in low- and middle-income countries (LMICs). Despite the rapid growth and inequitable distribution in NCDs, much of the human and social impact caused each year by NCD-related deaths could be averted through well-understood, cost-effective, feasible interventions ([@B1]).

More people worldwide die from cardiovascular diseases (CVDs)---mainly ischemic heart disease and stroke---than from any other cause ([@B2]). Population aging and growth, along with changes in the distribution of risk factors---mostly tobacco use, lack of physical activity, unhealthy diet, and harmful use of alcohol---have accelerated growth in the NCD disease burden within many LMICs ([@B3]).

Hypertension is the major contributor to the CVD burden and remains largely undertreated in many LMICs ([@B4]). Annually, hypertension is responsible for 7.6 million deaths worldwide (13.5% of all deaths), more than for any other individual risk factor ([@B4]). Approximately 54% of stroke and 47% of coronary heart disease in LMICs are attributable to high blood pressure ([@B4]). CVD is ranked as the leading cause of death in Latin America and the Caribbean (LAC) ([@B5], [@B6]). Every year, an estimated 1.6 million people die from CVD in the Americas, one-third of them before 70 years of age ([@B7]).

While hypertension affects between 20% and 40% of the adult population in the LAC region, control of hypertension has been prioritized unevenly. Indeed, in 2013, the Prospective Urban Rural Epidemiological Study, which included participants from four LAC countries (Argentina, Brazil, Chile, Colombia), reported an awareness rate of 57%; among those aware, a treatment rate of 53% (with 36% of those on treatment controlled); and a very low population-level control rate of 19%. All these figures reflect the challenge ahead. The causes for diagnosis, treatment, and control gaps are not completely clear. However, they seem partly due to differences in the level of development and governance of the health system, as well as disparities in access, coverage, and quality of health care services. The LAC region has significant socioeconomic inequalities, and countries are at different stages of economic and social development and organization of their health systems ([@B7]).

With hypertension representing a significant disease burden in the LAC region, it is crucial for all regional stakeholders to understand current activities, progress, and challenges for its control. Currently, there are many proven, effective interventions. If they were broadly scaled up, that would improve hypertension control and save millions of lives worldwide ([@B8]). However, most of these interventions do not have strategies to initiate, monitor, and sustain their delivery.

This is where late-stage (T4) translation research---research that studies optimal and sustainable strategies for delivering proven effective interventions---could tackle this current situation. Late-stage (T4) translation research comes at the end of the biomedical translation research spectrum. That continuum starts with fundamental discovery (T0) and goes on to translation into humans (T1), into patients (T2), and into clinical practice (T3). It concludes with (T4) translation, which takes effective interventions and studies their dissemination and implementation at the population level.

Late-stage (T4) translation research conducts studies in real-world settings, in the context where implementation will actually occur. The results can determine strategies for intervention delivery that are acceptable, affordable, and sustainable ([@B9]).

In an effort to address some of the major aspects related to hypertension control in the LAC region, this article focuses on two main objectives: 1) to identify the extent of the problem and the gaps pertaining to hypertension control in the LAC region and 2) to identify the potential role for late-stage (T4) translation research to tackle the current and future hypertension burden in the LAC region.

LATIN AMERICAN AND CARIBBEAN CALLS TO ACTION AND OTHER ACTIVITIES
=================================================================

In 2012, during the 28^th^ Pan American Sanitary Conference, ministers of health of the Americas endorsed the Pan American Health Organization (PAHO) Strategy for the Prevention and Control of Noncommunicable Diseases ([@B10]), along with a Regional Framework for NCD Prevention and Control. Both of those documents were later further developed in a PAHO publication titled *Plan of Action for the Prevention and Control of Noncommunicable Diseases in the Americas 2013-2019* ([@B11]). Both the Strategy and the Plan of Action focus on cardiovascular diseases, cancer, diabetes, and chronic respiratory disease, along with four NCD risk factors: tobacco, diet, physical inactivity, and alcohol. The Plan of Action is consistent with the World Health Organization (WHO) Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020 ([@B12]).

In 2012, a PAHO study done in collaboration with the Latin American and Caribbean Center on Health Science Information (BIREME) and other partners reported that among the 35 LAC countries, only 9 had recent representative data on hypertension from national studies ([@B7]). This leaves many countries falling short of having the critical information needed to understand trends and establish effective control policies.

The Salt Reduction Initiative in the Americas is focusing on the reformulation of processed foods to reduce their salt content, given that dietary salt intake is a major risk factor for developing hypertension. Started in 2013, this effort is coordinated by PAHO and based on WHO\'s "best buy" practices. It aims to prevent hypertension and cardiovascular diseases in the Americas ([@B13]). Targets and timelines for reduced salt content in processed foods have been developed for six LAC countries: Argentina, Brazil, Chile, Ecuador, Mexico, and Paraguay ([@B14]).

Countries in the Americas have NCD prevention and control plans ([@B15]) that are aligned with WHO global mandates. What is unique in the LAC region is that more emphasis is being placed on the control of hypertension. This has resulted in the 2019 target for achieving a population-level hypertension control rate of 35%. Meeting that standard will require that roughly 70% of those with hypertension know their status (awareness), that 70% of those who know their status are being treated, and that 70% of those being treated are being controlled ([@B16]).

To overcome many issues with hypertension control, PAHO, the U.S. Centers for Disease Control and Prevention (CDC), and other partners launched the Global Standardized Hypertension Treatment Project (GSHTP) in 2014 ([@B17]). The aim was to reduce the burden of CVD by developing and implementing standardized pharmacologic treatments for hypertension, thus leading to improved control rates. GSHTP has emphasized three major components: ([@B1]) standardized treatment protocols; ([@B2]) identification and sustained availability of a core set of affordable and effective hypertension drugs; and ([@B3]) registries for clinical tracking and performance evaluation. For the second component of the GSHTP, to improve the availability of drugs, PAHO is playing an important role through the PAHO Strategic Fund, which is an effective mechanism for improving access to and availability of essential medicines for NCDs ([@B18]). From 2014 to 2015, GSHTP was piloted in Barbados. The results were promising, with increases in blood pressure control rates, development of registries, and improved prescribing practices at primary care levels. In 2016, with technical support from PAHO and in collaboration CDC and others partners, a similar program was initiated in Chile, Colombia, and Cuba. The approach prioritized hypertension control and secondary prevention, with the ultimate goal of reducing the CVD burden. Key elements of the GSHTP approach have now been included in Global HEARTS, an international initiative for cardiovascular disease that is led by WHO, working in collaboration with other partners.

CURRENT CHALLENGES AND GAPS WITH HYPERTENSION IN LATIN AMERICA AND THE CARIBBEAN
================================================================================

It is crucial to understand why some national and regional strategies used in LAC for hypertension control have not worked, even where evidence-based clinical guidelines, treatments, and drug availability---or a combination of them---were employed. As in other LMICs globally ([@B9]), in the LAC region, health care performance and access and affordability of hypertension drugs varies from country to country. In addition, regulation regarding pricing is often lacking, leaving implementation of hypertension control initiatives still a major challenge. There is also a need to strengthen links between national health care systems and the community, including patients, their families, and community-based organizations working on hypertension control.

Recognizing the gaps inherent in managing NCDs is also an important challenge for the LAC region. PAHO has adopted and is promoting the well-known Chronic Care Model (CCM), an innovative, comprehensive model of care ([@B19], [@B20]). The CCM encourages patients in the self-management of their condition, by improving their skills. This requires involving a broad team, as well as coordination and task shifting. Among its components are linkages with community care organizations, resources, and policies; tools for decision support; and clinical information systems to monitor patient progress and clinical performance of the health care organizations. The ultimate goal is to achieve a productive interaction between patients and the health care team ([Figure 1](#f1){ref-type="fig"}) ([@B19]). At the same time, PAHO envisions late-stage (T4) translation research helping determine optimal and sustainable strategies to deliver this model.
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One crucial gap is the need for better research methods. This includes both mixed methods research designs and multilevel, multidimensional interventions promoted by late-stage (T4) translation research. PAHO recognizes the critical need to enhance the knowledge and skills required for late-stage (T4) translation research. Additional gaps include: 1) understanding how to improve access and quality of clinical care and 2) enhancing medication uptake while strengthening the functioning of primary health care systems. Late-stage (T4) translation research outputs will provide a better understanding of the sustainability and the costs of current and future interventions, which are all recognized as being highly important by WHO, PAHO, and LAC ministries of health.

OPPORTUNITIES FOR LATE-STAGE (T4) TRANSLATION RESEARCH TO ADDRESS HYPERTENSION TREATMENT AND CONTROL IN LATIN AMERICA AND THE CARIBBEAN
=======================================================================================================================================

Several LAC countries are currently developing comprehensive NCD control plans for cardiovascular diseases, diabetes, chronic respiratory diseases, and cancer, as well as their respective risk factors. As noted above, PAHO is working on implementing a comprehensive plan of action for the period 2013-2019 within the PAHO Strategy for the Prevention and Control of Noncommunicable Diseases. Specific Objective 3.3 of that Strategy focuses on the implementation of effective, evidence-based, and cost-effective interventions for the treatment and control of CVDs, hypertension, diabetes, cancers, and chronic respiratory diseases. This offers an opportunity to utilize late-stage (T4) translation research to determine the best strategies to deliver hypertension control within national and regional plans. Currently, such research is not necessarily incorporated in the decision-making process regarding hypertension control. Changing this could contribute to more cost-efficient and appropriate hypertension control approaches and practices.

Improved utilization of evidence-based interventions---which could be achieved through late-stage (T4) translation research---offers a distinctive opportunity for various stakeholders to work together on hypertension control in the LAC region. The key partners in the research include government agencies, PAHO, universities, research centers, nongovernmental organizations (NGOs), and health care organizations, as well as patients, their families, and other key actors in the health system.

There are already efficient collaborations in some LAC countries, but more comprehensive and integrated ones are needed. These types of partnerships could help in the control of hypertension by building required capacity and by leveraging resources for joint technical and financial assistance.

CONCLUSIONS
===========

Achieving hypertension control by addressing some of the major current gaps in the LAC region through public health interventions is challenging. It will require the engagement of all stakeholders, as well as the implementation of partnerships and strategic alliances. Efforts will be needed that target patient and health care provider awareness; appropriate lifestyle modifications; access to evidence-based treatment; high levels of medication availability, quality, and adherence; and adequate follow-up.

Late-stage (T4) translation research offers an excellent opportunity for contextualized chronic care models focusing on the major gaps pertaining to delivery of hypertension treatment and control. Moreover, late-stage (T4) translation research represents an opportunity to enhance much-needed public health interventions and concretely identify the optimal, affordable, sustainable delivery strategies needed for hypertension treatment and control both in individual countries and the entire LAC region.
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